Skip to content
B
BiotechEdge
Start 14-Day Free Trial

Apellis Pharmaceuticals + Biogen

pending

$APLS acquired by Biogen for $5.6B

Deal Summary

Deal Value
$5.6B
Price/Share
$41
Announced
Mar 31, 2026
Expected Close
TBD

Fund Positioning

6 of 20 tracked specialist biotech funds held $APLS — based on SEC 13F filings.

FundSharesValueEntryAt Announcement
Avoro Capital Advisors12.2M$307.0MMar 2025Yes
Deep Track Capital7.8M$194.7MDec 2025Yes
RTW Investments7.7M$192.6MDec 2025Yes
EcoR1 Capital3.4M$78.0MMar 2025Yes
OrbiMed Advisors2.4M$61.0MMar 2025Yes
Rock Springs Capital151K$3.8MMar 2025Yes
← All biotech acquisitions